Guang-Hong Tan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Guang-Hong Tan has a total of 131 co-authors. Here are the top co-authors by number of shared publications:
Feng-Ying Huang
NHC Key Laboratory of Tropical Disease Control, The Second Affiliated Hospital and School of Tropical Medicine, Hainan Medical University, Haikou, China
21 shared publicationsShu-Zhen Dai
NHC Key Laboratory of Tropical Disease Control, School of Life Sciences and Medical Technology, Hainan Medical University, Haikou, Hainan, 571199, China
17 shared publicationsYing-Ying Lin
NHC Key Laboratory of Tropical Disease Control, School of Life Sciences and Medical Technology, Hainan Academy of Medical Sciences, Hainan Medical University, Haikou, China
17 shared publications- Feng-Ying Huang
NHC Key Laboratory of Tropical Disease Control, School of Life Sciences and Medical Technology, Hainan Academy of Medical Sciences, Hainan Medical University, Haikou, China
12 shared publications - Wu-Ping Zheng
Department of Breast and Thyroid Surgery, The Second Affiliated Hospital of Hainan Medical University, Haikou, China
10 shared publications Yong-Hao Huang
Department of Breast and Thyroid Surgery, The Second Affiliated Hospital of Hainan Medical University and Key Laborato1y of Tropical Translational Medicine of Ministry of Education & School of Tropical Medicine, Hainan Medical University, Haikou 570311, China
10 shared publications
Latest Publications
- Open Access
- 19 June 2026
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 18 (7) , 1-33
Bacterialized tumor cells as vaccine
Tumor vaccines represent a promising modality in cancer immunotherapy, but the limited immunogenicity of whole-tumor cell vaccines (WTCVs) restricts their clinical translation. Here, we developed a novel bacterialized tumor cell (BTC) vaccine by coating amino-functionalized bacterial lysates onto the surface of tumor cells, a process we define as “bacterialization”. In vitro and in vivo experiments demonstrated that BTCs efficiently promote dendritic cell (DC) phagocytosis, maturation, and antigen cross-presentation, enhance DC migration to draining lymph nodes (DLNs), and remodel the DLN microenvironment by expanding tumor-specific CD8⁺ T cells and memory CD8⁺ T cells, while reducing terminally exhausted CD8⁺ T cells. BTC vaccination elicited robust tumor-specific cellular and humoral immunity, which synergistically suppressed tumor growth and metastasis in five syngeneic murine tumor models with negligible adverse effects. Furthermore, BTC vaccination reversed the immunosuppressive tumor microenvironment by increasing functional CD8⁺ T cell infiltration and reducing inhibitory immune subsets, and exhibited significant synergistic anti-tumor effects when combined with anti-PD-1 immune therapy. These findings demonstrate that BTCs represent a safe and effective novel WTCV candidate with strong clinical translation potential.
- 19 June 2026
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 18 (7) , 1-33
Open AccessBacterialized tumor cells as vaccine
Tumor vaccines represent a promising modality in cancer immunotherapy, but the limited immunogenicity of whole-tumor cell vaccines (WTCVs) restricts their clinical translation. Here, we developed a novel bacterialized tumor cell (BTC) vaccine by coating amino-functionalized bacterial lysates onto the surface of tumor cells, a process we define as “bacterialization”. In vitro and in vivo experiments demonstrated that BTCs efficiently promote dendritic cell (DC) phagocytosis, maturation, and antigen cross-presentation, enhance DC migration to draining lymph nodes (DLNs), and remodel the DLN microenvironment by expanding tumor-specific CD8⁺ T cells and memory CD8⁺ T cells, while reducing terminally exhausted CD8⁺ T cells. BTC vaccination elicited robust tumor-specific cellular and humoral immunity, which synergistically suppressed tumor growth and metastasis in five syngeneic murine tumor models with negligible adverse effects. Furthermore, BTC vaccination reversed the immunosuppressive tumor microenvironment by increasing functional CD8⁺ T cell infiltration and reducing inhibitory immune subsets, and exhibited significant synergistic anti-tumor effects when combined with anti-PD-1 immune therapy. These findings demonstrate that BTCs represent a safe and effective novel WTCV candidate with strong clinical translation potential.
- Open Access
- 23 April 2026
- Published by Elsevier in Translational Oncology
- Vol. 68, 102779
Toxicarioside H induces cytoprotective autophagy by hindering the progression of necroptosis in triple-negative breast cancer cells
- 23 April 2026
- Published by Elsevier in Translational Oncology
- Vol. 68, 102779
Open AccessToxicarioside H induces cytoprotective autophagy by hindering the progression of necroptosis in triple-negative breast cancer cells
- Open Access
- 30 March 2026
- Published by Spandidos Publications in Oncology Letters
- Vol. 31 (5) , 1-14
Lung squamous cell carcinoma downregulates haptoglobin expression to inhibit M2 macrophage ferroptosis via the hemoglobin‑dependent CD163/HO‑1 pathway
Lung squamous cell carcinoma (LUSC) is a highly malignant tumor that poses significant challenges for targeted therapy. Thus, there is a need to identify novel treatment targets. Acute-phase proteins (APPs) have been implicated in various physiological and pathophysiological processes, including cancer progression and ferroptosis. However, it remains unclear whether APPs serve a role in the progression and ferroptosis of LUSC. In the present study, bioinformatics analysis identified a haptoglobin (HP) gene as a hub gene in LUSC, and its expression levels were negatively associated with patient prognosis. HP was notably downregulated in LUSC and significantly enriched in the ferroptosis pathway. In vitro experiments demonstrated that overexpression of HP in LUSC cells did not induce ferroptosis, as there were no significant differences in lactate dehydrogenase (LDH) release, the frequency of 7-aminoactinomycin D (7-AAD)-positive cells, Fe2+ levels and lipid peroxidation among the cells in the LV-Ctrl, LV-HP, LV-Ctrl/Hb and LV-HP/Hb groups. However, when M2 macrophages were cultured with conditioned medium from LUSC cells overexpressing HP in the presence of hemoglobin (LV-HP/Hb group), there was a significant induction of ferroptosis in the M2 macrophages compared with those in the LV-Ctrl, LV-HP and LV-Ctrl/Hb and groups. This was evidenced by the increase in LDH release, the frequency of 7-AAD-positive cells, Fe2+ levels, lipid peroxidation and typical ultrastructural changes observed under transmission electron microscopy. Further mechanistic investigations revealed that the anti-CD163 antibody, the HO-1 inhibitor Tin protoporphyrin IX dichloride and the Fe2+ chelator deferoxamine effectively alleviated M2 macrophage ferroptosis in the LV-HP/Hb group. These results indicated that HP could promote M2 macrophage ferroptosis by promoting intracellular Fe2+ accumulation via a hemoglobin-dependent CD163/heme oxygenase 1 pathway, indicating a potential avenue for future investigations in LUSC research.
- 30 March 2026
- Published by Spandidos Publications in Oncology Letters
- Vol. 31 (5) , 1-14
Open AccessLung squamous cell carcinoma downregulates haptoglobin expression to inhibit M2 macrophage ferroptosis via the hemoglobin‑dependent CD163/HO‑1 pathway
Lung squamous cell carcinoma (LUSC) is a highly malignant tumor that poses significant challenges for targeted therapy. Thus, there is a need to identify novel treatment targets. Acute-phase proteins (APPs) have been implicated in various physiological and pathophysiological processes, including cancer progression and ferroptosis. However, it remains unclear whether APPs serve a role in the progression and ferroptosis of LUSC. In the present study, bioinformatics analysis identified a haptoglobin (HP) gene as a hub gene in LUSC, and its expression levels were negatively associated with patient prognosis. HP was notably downregulated in LUSC and significantly enriched in the ferroptosis pathway. In vitro experiments demonstrated that overexpression of HP in LUSC cells did not induce ferroptosis, as there were no significant differences in lactate dehydrogenase (LDH) release, the frequency of 7-aminoactinomycin D (7-AAD)-positive cells, Fe2+ levels and lipid peroxidation among the cells in the LV-Ctrl, LV-HP, LV-Ctrl/Hb and LV-HP/Hb groups. However, when M2 macrophages were cultured with conditioned medium from LUSC cells overexpressing HP in the presence of hemoglobin (LV-HP/Hb group), there was a significant induction of ferroptosis in the M2 macrophages compared with those in the LV-Ctrl, LV-HP and LV-Ctrl/Hb and groups. This was evidenced by the increase in LDH release, the frequency of 7-AAD-positive cells, Fe2+ levels, lipid peroxidation and typical ultrastructural changes observed under transmission electron microscopy. Further mechanistic investigations revealed that the anti-CD163 antibody, the HO-1 inhibitor Tin protoporphyrin IX dichloride and the Fe2+ chelator deferoxamine effectively alleviated M2 macrophage ferroptosis in the LV-HP/Hb group. These results indicated that HP could promote M2 macrophage ferroptosis by promoting intracellular Fe2+ accumulation via a hemoglobin-dependent CD163/heme oxygenase 1 pathway, indicating a potential avenue for future investigations in LUSC research.
- Open Access
- 2 June 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-15
Penicilazaphilone C triggers ferroptosis in triple-negative breast cancer cells via the MDM2/p53/SLC7 A11/GPX4 pathway
Penicilazaphilone C (PAC) is a novel azaphilone isolated by our research team. While known for its antitumor properties, the potential of PAC to trigger ferroptosis in triple-negative breast cancer (TNBC) cells remains unexplored. This study aims to assess the ferroptotic induction capability of PAC and elucidate the underlying molecular mechanisms. Our results showed that treatment with PAC demonstrated a dose- and time-dependent inhibition of growth in MDA-MB-231 and MDA-MB-436 cells. Flow cytometry analysis and lactate dehydrogenase assay revealed various forms of cell death induced by PAC in both cell lines. Specifically, flow cytometry analyzed 7-AAD-stained dead cells, and ferroptosis markers, such as lipid peroxidation BODIPY-C11 and Fe2+ ions, identified ferroptosis as the major type of cell death pathway induced by PAC. Moreover, co-administration of the ferroptosis inhibitor Fer-1 notably mitigated PAC-induced cell death, further highlighting ferroptosis as the primary mechanism through which PAC inhibits TNBC cell growth and proliferation. Further exploration of the molecular mechanisms unveiled that PAC modulated the expression of Mouse double minute 2 (MDM2), p53, SLC7A11, and GPX4. In vivo experiments using nude mouse models implanted with MDA-MB-231 and MDA-MB-436 cells demonstrated that PAC treatment effectively suppressed tumor growth, increased levels of BODIPY-C11 and Fe2+ ions in isolated single tumor cells, downregulated MDM2 expression, and upregulated p53, SLC7A11, and GPX4 expression. These results suggest that PAC hinders TNBC cell growth and proliferation by modulating the MDM2/p53/SLC7A11/GPX4 axis to induce ferroptosis, positioning PAC as a promising azaphilone candidate for TNBC therapy.
- 2 June 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-15
Open AccessPenicilazaphilone C triggers ferroptosis in triple-negative breast cancer cells via the MDM2/p53/SLC7 A11/GPX4 pathway
Penicilazaphilone C (PAC) is a novel azaphilone isolated by our research team. While known for its antitumor properties, the potential of PAC to trigger ferroptosis in triple-negative breast cancer (TNBC) cells remains unexplored. This study aims to assess the ferroptotic induction capability of PAC and elucidate the underlying molecular mechanisms. Our results showed that treatment with PAC demonstrated a dose- and time-dependent inhibition of growth in MDA-MB-231 and MDA-MB-436 cells. Flow cytometry analysis and lactate dehydrogenase assay revealed various forms of cell death induced by PAC in both cell lines. Specifically, flow cytometry analyzed 7-AAD-stained dead cells, and ferroptosis markers, such as lipid peroxidation BODIPY-C11 and Fe2+ ions, identified ferroptosis as the major type of cell death pathway induced by PAC. Moreover, co-administration of the ferroptosis inhibitor Fer-1 notably mitigated PAC-induced cell death, further highlighting ferroptosis as the primary mechanism through which PAC inhibits TNBC cell growth and proliferation. Further exploration of the molecular mechanisms unveiled that PAC modulated the expression of Mouse double minute 2 (MDM2), p53, SLC7A11, and GPX4. In vivo experiments using nude mouse models implanted with MDA-MB-231 and MDA-MB-436 cells demonstrated that PAC treatment effectively suppressed tumor growth, increased levels of BODIPY-C11 and Fe2+ ions in isolated single tumor cells, downregulated MDM2 expression, and upregulated p53, SLC7A11, and GPX4 expression. These results suggest that PAC hinders TNBC cell growth and proliferation by modulating the MDM2/p53/SLC7A11/GPX4 axis to induce ferroptosis, positioning PAC as a promising azaphilone candidate for TNBC therapy.
- Open Access
- 15 May 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-17
Toxicarioside H induces ferroptosis in triple-negative breast cancer cells through Nrf2/HO-1 pathway
Recent studies have identified novel cardiac glycosides from natural sources with potential anti-tumor properties. Toxicarioside H (ToxH) is a novel cardiac glycoside isolated by our collaborative research team. However, its ability to induce ferroptosis in triple-negative breast cancer (TNBC) cells has not been investigated. Therefore, this study evaluates whether ToxH has the capability of inducing ferroptosis and elucidates the underlying molecular mechanisms. Treatment with ToxH led to dose- and time-dependent growth inhibition in BT-549 and MDA-MB-468 cells. Flow cytometry analysis and lactate dehydrogenase assay revealed that ToxH induced various forms of cell death in both BT-549 and MDA-MB-468 cells. Examination through transmission electron microscopy, along with flow cytometry analysis of 7-AAD-stained dead cells and ferroptosis markers BODIPY-C11 and Fe2+ ions, identified various forms of cell death induced by ToxH, including apoptosis, autophagy, apoptotic necrosis, and ferroptosis. Co-treatment with the ferroptosis inhibitor Fer-1 significantly reduced ToxH-induced cell death, indicating that ToxH primarily inhibits TNBC cell growth by inducing ferroptosis. Further investigation into the molecular mechanisms revealed upregulation of Nrf2 and HO-1 expression by ToxH. Effective inhibition of ToxH-induced ferroptosis was achieved through shRNA-mediated knockdown of HO-1 expression. Animal experiments demonstrated that ToxH treatment markedly suppressed tumor growth compared to the control group, while co-administration of Fer-1 led to an increase in tumor growth. These findings suggest that ToxH suppresses TNBC cell growth by modulating the Nrf2/HO-1 signaling pathway to induce ferroptosis. ToxH presents itself as a promising cardiac glycoside compound for TNBC treatment, warranting further translational research.
- 15 May 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-17
Open AccessToxicarioside H induces ferroptosis in triple-negative breast cancer cells through Nrf2/HO-1 pathway
Recent studies have identified novel cardiac glycosides from natural sources with potential anti-tumor properties. Toxicarioside H (ToxH) is a novel cardiac glycoside isolated by our collaborative research team. However, its ability to induce ferroptosis in triple-negative breast cancer (TNBC) cells has not been investigated. Therefore, this study evaluates whether ToxH has the capability of inducing ferroptosis and elucidates the underlying molecular mechanisms. Treatment with ToxH led to dose- and time-dependent growth inhibition in BT-549 and MDA-MB-468 cells. Flow cytometry analysis and lactate dehydrogenase assay revealed that ToxH induced various forms of cell death in both BT-549 and MDA-MB-468 cells. Examination through transmission electron microscopy, along with flow cytometry analysis of 7-AAD-stained dead cells and ferroptosis markers BODIPY-C11 and Fe2+ ions, identified various forms of cell death induced by ToxH, including apoptosis, autophagy, apoptotic necrosis, and ferroptosis. Co-treatment with the ferroptosis inhibitor Fer-1 significantly reduced ToxH-induced cell death, indicating that ToxH primarily inhibits TNBC cell growth by inducing ferroptosis. Further investigation into the molecular mechanisms revealed upregulation of Nrf2 and HO-1 expression by ToxH. Effective inhibition of ToxH-induced ferroptosis was achieved through shRNA-mediated knockdown of HO-1 expression. Animal experiments demonstrated that ToxH treatment markedly suppressed tumor growth compared to the control group, while co-administration of Fer-1 led to an increase in tumor growth. These findings suggest that ToxH suppresses TNBC cell growth by modulating the Nrf2/HO-1 signaling pathway to induce ferroptosis. ToxH presents itself as a promising cardiac glycoside compound for TNBC treatment, warranting further translational research.
- Open Access
- 22 April 2025
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 187, 118085
3'-epi-12β-hydroxyfroside induces autophagic degradation of ABCG2 to overcome drug resistance in lung cancer cells
- 22 April 2025
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 187, 118085
Open Access3'-epi-12β-hydroxyfroside induces autophagic degradation of ABCG2 to overcome drug resistance in lung cancer cells
- Open Access
- 6 February 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (2) , e010150
Reinforcing cancer immunotherapy with engineered porous hollow mycobacterium tuberculosis loaded with tumor neoantigens
Background: Enhancing antigen cross-presentation is essential for the development of a tumor neoantigen vaccine. One approach is to stimulate antigen-presenting cells (APCs) to uptake neoantigens. Mycobacterium tuberculosis (MTb) contains pathogen-associated molecular patterns (PAMPs) recognized by APCs and adhesion molecules that facilitate MTb invasion of APCs. Therefore, we suggest using MTb as a carrier to enhance APC phagocytosis of neoantigens, thereby promoting antigen cross-presentation. Methods: The successful preparation of the MTb carrier (phMTb) was confirmed through electron and confocal microscopy. Fluorescence microscopy was used to detect PAMPs and adhesion molecules on phMTb as well as to observe its role in aiding dendritic cells (DCs) in antigen uptake into endosomes or lysosomes. Flow cytometry was used to assess the retention of PAMPs and adhesion molecules on phMTb, investigate antigen uptake by DCs, evaluate their activation and maturation status, examine the presentation of tumor neoantigens, and analyze immune cells in draining lymph nodes and tumor tissues. The efficacy of phMTb vaccine formulations in combination with anti-programmed cell death protein 1 (PD-1) antibody therapy was assessed using the MC38 mouse tumor models. Adverse effects were evaluated through H&E staining of major organs, assessment of reproductive capability and detection of biochemical indices. Results: The engineered porous hollow phMTb carrier successfully encapsulated model tumor neoantigens, with or without the adjuvant CpG. The phMTb retained PAMPs and adhesion molecules on its surface, similar to the parental MTb, thereby enhancing DC uptake of phMTb and its formulations containing tumor neoantigens and CpG. Vaccines formulated with phMTb facilitated DC maturation, activation, cross-presentation of tumor neoantigens, and promoted migration of phMTb-laden DCs to lymph nodes, enhancing effector and memory CD8+ T lymphocyte function. In murine tumor models, immunization with phMTb-formulated neoantigen vaccines elicited a robust tumor-specific cytotoxic T lymphocyte immune response with minimal adverse effects. Additionally, vaccination with phMTb-formulated neoantigen vaccines effectively reversed the tumor’s immune-suppressive microenvironment. Concurrent administration of the PD-1 antibody with the phMTb-formulated neoantigen vaccine exhibited significant synergistic therapeutic effects. Conclusions: The results of our study highlight the potential clinical translation of personalized tumor neoantigen vaccines using the phMTb carrier.
- 6 February 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (2) , e010150
Open AccessReinforcing cancer immunotherapy with engineered porous hollow mycobacterium tuberculosis loaded with tumor neoantigens
Background: Enhancing antigen cross-presentation is essential for the development of a tumor neoantigen vaccine. One approach is to stimulate antigen-presenting cells (APCs) to uptake neoantigens. Mycobacterium tuberculosis (MTb) contains pathogen-associated molecular patterns (PAMPs) recognized by APCs and adhesion molecules that facilitate MTb invasion of APCs. Therefore, we suggest using MTb as a carrier to enhance APC phagocytosis of neoantigens, thereby promoting antigen cross-presentation. Methods: The successful preparation of the MTb carrier (phMTb) was confirmed through electron and confocal microscopy. Fluorescence microscopy was used to detect PAMPs and adhesion molecules on phMTb as well as to observe its role in aiding dendritic cells (DCs) in antigen uptake into endosomes or lysosomes. Flow cytometry was used to assess the retention of PAMPs and adhesion molecules on phMTb, investigate antigen uptake by DCs, evaluate their activation and maturation status, examine the presentation of tumor neoantigens, and analyze immune cells in draining lymph nodes and tumor tissues. The efficacy of phMTb vaccine formulations in combination with anti-programmed cell death protein 1 (PD-1) antibody therapy was assessed using the MC38 mouse tumor models. Adverse effects were evaluated through H&E staining of major organs, assessment of reproductive capability and detection of biochemical indices. Results: The engineered porous hollow phMTb carrier successfully encapsulated model tumor neoantigens, with or without the adjuvant CpG. The phMTb retained PAMPs and adhesion molecules on its surface, similar to the parental MTb, thereby enhancing DC uptake of phMTb and its formulations containing tumor neoantigens and CpG. Vaccines formulated with phMTb facilitated DC maturation, activation, cross-presentation of tumor neoantigens, and promoted migration of phMTb-laden DCs to lymph nodes, enhancing effector and memory CD8+ T lymphocyte function. In murine tumor models, immunization with phMTb-formulated neoantigen vaccines elicited a robust tumor-specific cytotoxic T lymphocyte immune response with minimal adverse effects. Additionally, vaccination with phMTb-formulated neoantigen vaccines effectively reversed the tumor’s immune-suppressive microenvironment. Concurrent administration of the PD-1 antibody with the phMTb-formulated neoantigen vaccine exhibited significant synergistic therapeutic effects. Conclusions: The results of our study highlight the potential clinical translation of personalized tumor neoantigen vaccines using the phMTb carrier.
- 2 December 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 144, 113714
Progesterone suppresses rhinovirus-induced airway inflammation by inhibiting neutrophil infiltration and extracellular traps formation
- 2 December 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 144, 113714
Progesterone suppresses rhinovirus-induced airway inflammation by inhibiting neutrophil infiltration and extracellular traps formation
- Open Access
- 26 July 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-21
Progesterone modulates the immune microenvironment to suppress ovalbumin-induced airway inflammation by inhibiting NETosis
Studies have demonstrated that prior to puberty, girls have a lower incidence and severity of asthma symptoms compared to boys. This study aimed to explore the role of progesterone (P4), a sex hormone, in reducing inflammation and altering the immune microenvironment in a mouse model of allergic asthma induced by OVA. Female BALB/c mice with or without ovariectomy to remove the influence of sex hormones were used for the investigations. Serum, bronchoalveolar lavage fluid (BALF), and lung tissue samples were collected for analysis. The results indicated that P4 treatment was effective in decreasing inflammation and mucus secretion in the lungs of OVA-induced allergic asthma mice. P4 treatment also reduced the influx of inflammatory cells into the BALF and increased the levels of Th1 and Th17 cytokines while decreasing the levels of Th2 and Treg cytokines in both BALF and lung microenvironment CD45+ T cells. Furthermore, P4 inhibited the infiltration of inflammatory cells into the lungs, suppressed NETosis, and reduced the number of pulmonary CD4+ T cells while increasing the number of regulatory T cells. The neutrophil elastase inhibitor GW311616A also suppressed airway inflammation and mucus production and modified the secretion of immune Th1, Th2, Th17, and Treg cytokines in lung CD45+ immune cells. These changes led to an alteration of the immunological milieu with increased Th1 and Th17 cells, accompanied by decreased Th2, Treg, and CD44+ T cells, similar to the effects of P4 treatment. Treatment with P4 inhibited NETosis by suppressing the p38 pathway activation, leading to reduced reactive oxygen species production. Moreover, P4 treatment hindered the release of double-stranded DNA during NETosis, thereby influencing the immune microenvironment in the lungs. These findings suggest that P4 treatment may be beneficial in reducing inflammation associated with allergic asthma by modulating the immune microenvironment. In conclusion, this research indicates the potential of P4 as a therapeutic agent for ameliorating inflammation in OVA-induced allergic asthma mice.
- 26 July 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-21
Open AccessProgesterone modulates the immune microenvironment to suppress ovalbumin-induced airway inflammation by inhibiting NETosis
Studies have demonstrated that prior to puberty, girls have a lower incidence and severity of asthma symptoms compared to boys. This study aimed to explore the role of progesterone (P4), a sex hormone, in reducing inflammation and altering the immune microenvironment in a mouse model of allergic asthma induced by OVA. Female BALB/c mice with or without ovariectomy to remove the influence of sex hormones were used for the investigations. Serum, bronchoalveolar lavage fluid (BALF), and lung tissue samples were collected for analysis. The results indicated that P4 treatment was effective in decreasing inflammation and mucus secretion in the lungs of OVA-induced allergic asthma mice. P4 treatment also reduced the influx of inflammatory cells into the BALF and increased the levels of Th1 and Th17 cytokines while decreasing the levels of Th2 and Treg cytokines in both BALF and lung microenvironment CD45+ T cells. Furthermore, P4 inhibited the infiltration of inflammatory cells into the lungs, suppressed NETosis, and reduced the number of pulmonary CD4+ T cells while increasing the number of regulatory T cells. The neutrophil elastase inhibitor GW311616A also suppressed airway inflammation and mucus production and modified the secretion of immune Th1, Th2, Th17, and Treg cytokines in lung CD45+ immune cells. These changes led to an alteration of the immunological milieu with increased Th1 and Th17 cells, accompanied by decreased Th2, Treg, and CD44+ T cells, similar to the effects of P4 treatment. Treatment with P4 inhibited NETosis by suppressing the p38 pathway activation, leading to reduced reactive oxygen species production. Moreover, P4 treatment hindered the release of double-stranded DNA during NETosis, thereby influencing the immune microenvironment in the lungs. These findings suggest that P4 treatment may be beneficial in reducing inflammation associated with allergic asthma by modulating the immune microenvironment. In conclusion, this research indicates the potential of P4 as a therapeutic agent for ameliorating inflammation in OVA-induced allergic asthma mice.
- Open Access
- 24 June 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (6) , e0305863
Rosuvastatin attenuates airway inflammation and remodeling in a chronic allergic asthma model through modulation of the AMPKα signaling pathway
The efficacy of rosuvastatin in reducing allergic inflammation has been established. However, its potential to reduce airway remodeling has yet to be explored. This study aimed to evaluate the efficacy of rosuvastatin in reducing airway inflammation and remodeling in a mouse model of chronic allergic asthma induced by sensitization and challenge with OVA. Histology of the lung tissue and the number of inflammatory cells in bronchoalveolar lavage fluid (BALF) showed a marked decrease in airway inflammation and remodeling in mice treated with rosuvastatin, as evidenced by a decrease in goblet cell hyperplasia, collagen deposition, and smooth muscle hypertrophy. Furthermore, levels of inflammatory cytokines, angiogenesis-related factors, and OVA-specific IgE in BALF, plasma, and serum were all reduced upon treatment with rosuvastatin. Western blotting was employed to detect AMPK expression, while immunohistochemistry staining was used to observe the expression of remodeling signaling proteins such as α-SMA, TGF-β, MMP-9, and p-AMPKα in the lungs. It was found that the activity of 5’-adenosine monophosphate-activated protein kinase alpha (AMPKα) was significantly lower in the lungs of OVA-induced asthmatic mice compared to Control mice. However, the administration of rosuvastatin increased the ratio of phosphorylated AMPK to total AMPKα, thus inhibiting the formation of new blood vessels, as indicated by CD31-positive staining mainly in the sub-epithelial region. These results indicate that rosuvastatin can effectively reduce airway inflammation and remodeling in mice with chronic allergic asthma caused by OVA, likely due to the reactivation of AMPKα and a decrease in angiogenesis.
- 24 June 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (6) , e0305863
Open AccessRosuvastatin attenuates airway inflammation and remodeling in a chronic allergic asthma model through modulation of the AMPKα signaling pathway
The efficacy of rosuvastatin in reducing allergic inflammation has been established. However, its potential to reduce airway remodeling has yet to be explored. This study aimed to evaluate the efficacy of rosuvastatin in reducing airway inflammation and remodeling in a mouse model of chronic allergic asthma induced by sensitization and challenge with OVA. Histology of the lung tissue and the number of inflammatory cells in bronchoalveolar lavage fluid (BALF) showed a marked decrease in airway inflammation and remodeling in mice treated with rosuvastatin, as evidenced by a decrease in goblet cell hyperplasia, collagen deposition, and smooth muscle hypertrophy. Furthermore, levels of inflammatory cytokines, angiogenesis-related factors, and OVA-specific IgE in BALF, plasma, and serum were all reduced upon treatment with rosuvastatin. Western blotting was employed to detect AMPK expression, while immunohistochemistry staining was used to observe the expression of remodeling signaling proteins such as α-SMA, TGF-β, MMP-9, and p-AMPKα in the lungs. It was found that the activity of 5’-adenosine monophosphate-activated protein kinase alpha (AMPKα) was significantly lower in the lungs of OVA-induced asthmatic mice compared to Control mice. However, the administration of rosuvastatin increased the ratio of phosphorylated AMPK to total AMPKα, thus inhibiting the formation of new blood vessels, as indicated by CD31-positive staining mainly in the sub-epithelial region. These results indicate that rosuvastatin can effectively reduce airway inflammation and remodeling in mice with chronic allergic asthma caused by OVA, likely due to the reactivation of AMPKα and a decrease in angiogenesis.